摘要
目的评价C反应蛋白（CRP）作为新生儿细菌感染停药指标的临床安全性。方法符合病例入选标准的150例新生儿根据出生后检测的CRP值分为无感染组42例和感染组108例。感染组又分为CRP指导组54例和7d治疗组54例。CRP指导组根据每天测得的CRP作为停用抗生素的指标；7d治疗组应用抗生素至少7d，待临床症状消失和CRP〈8mg／L后停药。结果无感染组2．38％的患者需再次接受抗生素治疗，感染组无患者需再次接受抗生素治疗者。抗生素疗程：无感染组为3d，CRP指导组为4～11（4．6±1．2）d，7d治疗组为7～14（9．8±1．6）d；3组之间抗生素疗程均有显著性差异（P均〈0．01）；而再感染发生率无显著性差异（P〉0．05）。结论CRP可作为新生儿细菌感染停用抗生素的安全有效指标，可明显缩短抗生素疗程，而不增加感染复发率。
Objective It is to evaluate the clinical safety of C reaction protein （CRP） as drug withdrawal index in bacterial infection of neonate. Methods 150 neonates who were in line with selected standard were divided into free from infection group in which there was 42 cases and infection group in which there was 108 cases according to the CRP value detected. Infection group was divided into CRP guiding group in which there was 54 cases and seven day＇ s treatment group in which there was 54 cases once again. The level of CPR everyday was regarded as the target of stopping using antibiotic in CRP guiding group. Seven day＇ s treatment group had treated for least 7 days and the antibiotic stopped to use if clinical symptom disappeared or the levels of CRP was below 8 mg/L. Results 2.38% in free from infection group was treated with antibiotic again, while there was no cases in infection group. The course of antibiotic treatment were three days in free from infection group, 4 - 14 （4.6 ± 1.2） d in CPR guiding group and 7 - 14 （9.8 ± 1.6） d in seven day＇ s treatment group, and there were significant difference on course of antibiotic treatment among the three groups （ all P 〈 0.01 ） , while there was no significant difference on the ratio of reinfection （P 〉 0.05 ）. Conclusion CPR is a safe, effective index as stopping using antibiotic in bacterial infection of neonate. It can obviously shorten the course of antibiotic treatment but can not increase the ratio of relapse rate.
出处
《现代中西医结合杂志》
CAS
2010年第14期1704-1705,共2页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
CRP
新生儿
细菌感染
抗生素
C reaction protein
neonate
bacterial infection
antibiotic
